Last quarter (Q ), CNBX Pharmaceuticals's total revenue was $40.64K, an increase of Infinity% from the same quarter last year. In Q, CNBX Pharmaceuticals's net income was $-325.46K. See CNBX Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 23	Aug 22	Aug 21	Aug 20	Aug 19
Total Revenue	$ 540.24K	$ 410.17K	-	-	$ 7.16K	$ 9.84K
Cost of Revenue	$ 6.22K	-	-	-	-	-
Gross Profit	$ 534.02K	$ 410.17K	-	-	-	-
Operating Expense	$ 1.25M	$ 1.34M	$ -728.87K	$ -142.69K	$ 3.05M	$ 3.31M
Operating Income	$ -712.91K	$ -931.38K	$ 728.87K	$ 142.69K	$ -3.04M	$ -3.30M
Net Non Operating Interest Income Expense	$ -12.63K	$ -1.17K	$ 1.27K	$ 2.39K	$ -68.13K	$ -18.35K
Other Income Expense	$ -40.57K	$ -52.62K	$ -769.28K	$ -594.27K	$ -4.36M	$ 4.45M
Pretax Income	$ -724.96K	$ -931.38K	$ 2.00M	$ 1.25M	$ -7.47M	$ 1.13M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -1.23M	$ -3.71M	$ -3.72M	$ -3.19M	$ -7.47M	$ 1.13M
Basic EPS	$ -0.06	$ -0.42	$ -3.59	$ -34.56K	$ -12.00	$ 0.02
Diluted EPS	$ -0.06	$ -0.42	$ -3.59	$ -34.56K	$ -12.00	$ 0.02
Basic Average Shares	$ 90.83M	$ 8.82M	$ 1.22M	$ 138.52M	$ 1.12M	$ 132.45M
Diluted Average Shares	$ 90.83M	$ 8.82M	$ 1.22M	-	$ 1.12M	$ 132.45M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.25M	$ 1.34M	$ -728.87K	$ -142.69K	$ 3.05M	$ 3.31M
Interest Expense	-	-	-	-	$ 8.13K	$ 18.35K
Net Income From Continuing And Discontinued Operation	$ -1.23M	$ -3.71M	$ -3.72M	$ -3.19M	$ -7.47M	$ 1.13M
Normalized Income	$ -499.66K	$ -586.68K	-	-	$ -7.47M	$ 1.07M
EBIT	$ -712.33K	$ -930.21K	$ 2.00M	$ 1.25M	$ -7.46M	$ 1.15M
EBITDA	$ -561.53K	$ -768.14K	$ 2.20M	$ 1.47M	$ -7.24M	$ 1.34M

Currency in USD

CNBX Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing